The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users

Journal of Theoretical Biology

Volumn 333, Issue , 2013, Pages 126-134

  De Vos, Anneke S ^a   Kretzschmar, Mirjam E E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Epidemiology; Mathematical modelling; Risk variability

Indexed keywords

BLOOD; DRUG USER; EPIDEMIOLOGY; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; LIMITING FACTOR; NUMERICAL MODEL; RISK ASSESSMENT;

ARTICLE; HEPATITIS C; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK REDUCTION;

EPIDEMIOLOGY; MATHEMATICAL MODELLING; RISK VARIABILITY;

BLOOD-BORNE PATHOGENS; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

HEPATITIS C VIRUS;

EID: 84879495312     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2013.05.017     Document Type: Article

References (29)

1. Anderson R., Hanson M. Potential public health impact of imperfect HIV type 1 vaccines. J. Infect. Dis. 2005, 191:S85-S96.
2. Chow L., Fan M., Feng Z. Dynamics of a multigroup epidemiological model with group-targeted vaccination strategies. J. Theor. Biol. 2011, 291:56-64.
3. Corson S., Greenhalgh D., Hutchinson S.J. A time since onset of injection model for hepatitis C spread amongst injecting drug users. J. Math. Biol. 2012, 28. http://dx.doi.org/10.1007/s00285-012-0577-y.
4. Des Jarlais D.C., Padian N. Strategies for universalistic and targeted HIV prevention. J. Acquire Immune Defic. Syndr. Hum. Retrovirology 1997, 16:127-136.
5. de Vos A.S., van der Helm J.J., Prins M., Kretzschmar M.E. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users. Epidemics 2012, 4:57-67.
6. de Vos, A.S., van der Helm, J.J., Matser, A., Prins, M., Kretzschmar, M.E., 2013. Decline in incidence of HIV and Hepatitis C Virus infection among injecting drug users in Amsterdam: evidence for harm reduction? Addiction, doi: http://dx.doi.org/10.1111/add.12125.
7. Diekmann O., Heesterbeek J.A., Roberts M.G. The construction of next-generation matrices for compartmental epidemic models. J. R. Soc. Interface 2010, 7:873-885.
8. Dodd P.J., White P.J., Garnett G.P. Notions of synergy for combinations of interventions against infectious diseases in heterogeneously mixing populations. Math. Biosci. 2010, 227:94-104.
9. EMCDDA, 2012. Annual Report on the State of the Drugs Problem in Europe, Lisbon. ISBN/ISSN:1609-6150.
10. Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 1996, 86:655-661.
11. Genberg B.L., Gange S.J., Go V.F., Celentano D.D., Kirk G.D., Mehta S.H. Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland. Am. J. Epidemiol. 2011, 173:829-836.
12. Grassly N.C., Garnett G.P. The future of the HIV pandemic. Bull. World Health Organ. 2005, 83:378-382.
13. Hagan H., Des Jarlais D.C. HIV and HCV infection among injecting drug users. Mt. Sinai J. Med. 2000, 67:423-428.
14. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent Hepatitis C Virus infection in people who inject drugs. J. Infect. Dis. 2011, 204:74-83.
15. Hutchinson S.J., Taylor A., Goldberg D.J., Gruer L. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-1994. implications for control and prevention of blood-borne viruses. Addiction 2000, 95:931-940.
16. Koopman J.S., Simon C.P., Riolo C.P. When to control endemic infections by focusing on high-risk groups. Epidemiology 2005, 16:621-627.
17. Li J., Gilmour S., Zhang H., Koyanagi A., Shibuya K. The epidemiological impact and cost-effectiveness of HIV testing antiretroviral, treatment and harm reduction programs. AIDS 2012, 16:2069-2078.
18. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A., Wodak A., Panda S., Tyndall M., Toufik A., Mattick R.P. Global epidemiology of injecting drug use and HIV among people who inject drugs. a systematic review. Lancet 2008, 372:1733-1745.
19. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., Myers B., Ambekar A., Strathdee S.A. HIV prevention, treatment, and care services for people who inject drugs. a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028.
20. Nordén L., Lidman C. Differentiated risk behaviour for HIV and hepatitis among injecting drug users (IDUs). Scand. J. Infect. Dis. 2005, 37:493-496.
21. Norden L., Saxon L., Kåberg M., Käll K., Franck J., Lidman C. Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County, Sweden. Scand. J. Infect. Dis. 2009, 41:727-734.
22. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing Hepatitis C and human immunodeficiency virus transmission among injecting drug users. a review of reviews. Addiction 2010, 105:844-859.
23. Pharris A., Wiessing L., Sfetcu O., Hedrich D., Botescu A., Fotiou A., Nikolopoulos G.K., Malliori M., Salminen M., Suk J.E., Griffiths P., van de Laar M.J. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011, 16. pii=20032.
24. Philbin M., Pollini R.A., Ramos R., Lozada R., Brouwer K.C., Ramos M.E., Firestone-Cruz M., Case P., Strathdee S.A. Shooting gallery attendance among IDUs in Tijuana and Ciudad Juarez, Mexico. correlates, prevention opportunities, and the role of the environment. AIDS Behav. 2008, 12:552-560.
25. Sutton A.J., Hope V.D., Mathei C., Mravcik V., Sebakova H., Vallejo F., Suligoi B., Brugal M.T., Ncube F., Wiessing L., Kretzschmar M. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union. a modelling study. J. Viral Hepatitis 2008, 15:809-816.
26. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., May M., Taylor A., De Angelis D., Cameron S., Parry J., Lyons M., Goldberg D., Allen E., Hickman M. The impact of needle and syringe provision and opiate substitution therapy on the incidence of Hepatitis C Virus in injecting drug users. pooling of UK evidence. Addiction 2011, 106:1978-1988.
27. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and Hepatitis C Virus. evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102:1454-1462.
28. Vickerman P., Hickman M. The effect of epidemiological setting on the impact of harm reduction targeting injecting drug users. Harm Reduction. Evidence, Impacts and Challenges 2010, 165-188. EMCDDA Monograph, Lisbon, (Chapter 6). T. Rhodes, D. Hedrich (Eds.).
29. Vickerman P., Hickman M., Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing. London case study. Int. J. Epidemiol. 2007, 36:396-405.